CoChat
Sign Up
Cited by 139Drug Transport and Resistance MechanismsGut microbiota and healthCholesterol and Lipid Metabolism

Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets

Open access
Ferrell, Jessica M., Chiang, John Y. L.·2019·Diabetes & Metabolism Journal
DOI 10.4093/dmj.2019.0043PMC PMC6581552
Open this paper in CoChat — free accountOpen PDF

Abstract

Diabetes and obesity have reached an epidemic status worldwide. Diabetes increases the risk for cardiovascular disease and non-alcoholic fatty liver disease. Primary bile acids are synthesized in hepatocytes and are transformed to secondary bile acids in the intestine by gut bacteria. Bile acids are nutrient sensors and metabolic integrators that regulate lipid, glucose, and energy homeostasis by activating nuclear farnesoid X receptor and membrane Takeda G protein-coupled receptor 5. Bile acids control gut bacteria overgrowth, species population, and protect the integrity of the intestinal barrier. Gut bacteria, in turn, control circulating bile acid composition and pool size. Dysregulation of bile acid homeostasis and dysbiosis causes diabetes and obesity. Targeting bile acid signaling and the gut microbiome have therapeutic potential for treating diabetes, obesity, and non-alcoholic fatty liver disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4093/dmj.2019.0043

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 115

  1. [1]Rowley WR Bezold C Arikan Y Byrne E Krohe S Diabetes 2030: insights from yesterday, today, and future trends Popul Health Manag 2017 20 6 12 27124621 PMC5278808
  2. [2]Finkelstein EA Khavjou OA Thompson H Trogdon JG Pan L Sherry B Dietz W Obesity and severe obesity forecasts through 2030 Am J Prev Med 2012 42 563 570 22608371
  3. [3]Targher G Marchesini G Byrne CD Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: causal association or epiphenomenon? Diabetes Metab 2016 42 142 156 27142870
  4. [5]Lonardo A Nascimbeni F Mantovani A Targher G Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 2018 68 335 352 29122390
  5. [6]Targher G Byrne CD Lonardo A Zoppini G Barbui C Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis J Hepatol 2016 65 589 600 27212244
  6. [7]Ma J Hwang SJ Pedley A Massaro JM Hoffmann U Chung RT Benjamin EJ Levy D Fox CS Long MT Bi-directional analysis between fatty liver and cardiovascular disease risk factors J Hepatol 2017 66 390 397 27729222 PMC5250546
  7. [8]Chimakurthi CR Rowe IA Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease J Hepatol 2016 65 1265 1266 27498134
  8. [10]Ginsberg HN Zhang YL Hernandez-Ono A Metabolic syndrome: focus on dyslipidemia Obesity (Silver Spring) 2006 14 Suppl 1 41S 49S 16642962
  9. [11]Brunt EM Pathology of nonalcoholic fatty liver disease Nat Rev Gastroenterol Hepatol 2010 7 195 203 20195271
  10. [12]Machado MV Diehl AM Pathogenesis of nonalcoholic steatohepatitis Gastroenterology 2016 150 1769 1777 26928243 PMC4887389
  11. [13]Hardy T Oakley F Anstee QM Day CP Nonalcoholic fatty liver disease: pathogenesis and disease spectrum Annu Rev Pathol 2016 11 451 496 26980160
  12. [14]Haas JT Francque S Staels B Pathophysiology and mechanisms of nonalcoholic fatty liver disease Annu Rev Physiol 2016 78 181 205 26667070
  13. [15]Farrell GC Larter CZ Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 2006 43 2 Suppl 1 S99 S112 16447287
  14. [16]Chiang JY Bile acids: regulation of synthesis J Lipid Res 2009 50 1955 1966 19346330 PMC2739756
  15. [17]Prawitt J Caron S Staels B Bile acid metabolism and the pathogenesis of type 2 diabetes Curr Diab Rep 2011 11 160 166 21431855 PMC3338411
  16. [18]Haeusler RA Astiarraga B Camastra S Accili D Ferrannini E Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids Diabetes 2013 62 4184 4191 23884887 PMC3837033
  17. [19]Haeusler RA Pratt-Hyatt M Welch CL Klaassen CD Accili D Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia Cell Metab 2012 15 65 74 22197325 PMC3253887
  18. [20]Chiang JYL Ferrell JM Bile acid metabolism in liver pathobiology Gene Expr 2018 18 71 87 29325602 PMC5954621
  19. [21]Chiang JYL Bile acid metabolism and signaling in liver disease and therapy Liver Res 2017 1 3 9 29104811 PMC5663306
  20. [23]Makishima M Okamoto AY Repa JJ Tu H Learned RM Luk A Hull MV Lustig KD Mangelsdorf DJ Shan B Identification of a nuclear receptor for bile acids Science 1999 284 1362 1365 10334992
  21. [24]Parks DJ Blanchard SG Bledsoe RK Chandra G Consler TG Kliewer SA Stimmel JB Willson TM Zavacki AM Moore DD Lehmann JM Bile acids: natural ligands for an orphan nuclear receptor Science 1999 284 1365 1368 10334993
  22. [26]Goodwin B Gauthier KC Umetani M Watson MA Lochansky MI Collins JL Leitersdorf E Mangelsdorf DJ Kliewer SA Repa JJ Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor Proc Natl Acad Sci U S A 2003 100 223 228 12509506 PMC140933
  23. [27]Maruyama T Miyamoto Y Nakamura T Tamai Y Okada H Sugiyama E Nakamura T Itadani H Tanaka K Identification of membrane-type receptor for bile acids (M-BAR) Biochem Biophys Res Commun 2002 298 714 719 12419312
  24. [28]Studer E Zhou X Zhao R Wang Y Takabe K Nagahashi M Pandak WM Dent P Spiegel S Shi R Xu W Liu X Bohdan P Zhang L Zhou H Hylemon PB Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes Hepatology 2012 55 267 276 21932398 PMC3245352
  25. [29]Raufman JP Cheng K Zimniak P Activation of muscarinic receptor signaling by bile acids: physiological and medical implications Dig Dis Sci 2003 48 1431 1444 12924634
  26. [30]Lefebvre P Cariou B Lien F Kuipers F Staels B Role of bile acids and bile acid receptors in metabolic regulation Physiol Rev 2009 89 147 191 19126757
  27. [31]Sinal CJ Tohkin M Miyata M Ward JM Lambert G Gonzalez FJ Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 2000 102 731 744 11030617
  28. [32]Li T Chiang JY Bile acid signaling in metabolic disease and drug therapy Pharmacol Rev 2014 66 948 983 25073467 PMC4180336
  29. [33]Duran-Sandoval D Mautino G Martin G Percevault F Barbier O Fruchart JC Kuipers F Staels B Glucose regulates the expression of the farnesoid X receptor in liver Diabetes 2004 53 890 898 15047603
  30. [34]Ma K Saha PK Chan L Moore DD Farnesoid X receptor is essential for normal glucose homeostasis J Clin Invest 2006 116 1102 1109 16557297 PMC1409738
  31. [35]Cariou B van Harmelen K Duran-Sandoval D van Dijk TH Grefhorst A Abdelkarim M Caron S Torpier G Fruchart JC Gonzalez FJ Kuipers F Staels B The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice J Biol Chem 2006 281 11039 11049 16446356
  32. [36]Zhang Y Lee FY Barrera G Lee H Vales C Gonzalez FJ Willson TM Edwards PA Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice Proc Natl Acad Sci U S A 2006 103 1006 1011 16410358 PMC1347977
  33. [37]Watanabe M Horai Y Houten SM Morimoto K Sugizaki T Arita E Mataki C Sato H Tanigawara Y Schoonjans K Itoh H Auwerx J Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure J Biol Chem 2011 286 26913 26920 21632533 PMC3143650
  34. [38]Dufer M Horth K Wagner R Schittenhelm B Prowald S Wagner TF Oberwinkler J Lukowski R Gonzalez FJ Krippeit-Drews P Drews G Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition Diabetes 2012 61 1479 1489 22492528 PMC3357280
  35. [39]Keitel V Reinehr R Gatsios P Rupprecht C Gorg B Selbach O Haussinger D Kubitz R The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells Hepatology 2007 45 695 704 17326144
  36. [40]Keitel V Ullmer C Haussinger D The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes Biol Chem 2010 391 785 789 20623999
  37. [42]Keitel V Cupisti K Ullmer C Knoefel WT Kubitz R Haussinger D The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders Hepatology 2009 50 861 870 19582812
  38. [43]Donepudi AC Boehme S Li F Chiang JY G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice Hepatology 2017 65 813 827 27351453 PMC5195921
  39. [45]Keitel V Donner M Winandy S Kubitz R Haussinger D Expression and function of the bile acid receptor TGR5 in Kupffer cells Biochem Biophys Res Commun 2008 372 78 84 18468513
  40. [47]Broeders EP Nascimento EB Havekes B Brans B Roumans KH Tailleux A Schaart G Kouach M Charton J Deprez B Bouvy ND Mottaghy F Staels B van Marken Lichtenbelt WD Schrauwen P The bile acid chenodeoxycholic acid increases human brown adipose tissue activity Cell Metab 2015 22 418 426 26235421
  41. [48]Vassileva G Golovko A Markowitz L Abbondanzo SJ Zeng M Yang S Hoos L Tetzloff G Levitan D Murgolo NJ Keane K Davis HR Jr Hedrick J Gustafson EL Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation Biochem J 2006 398 423 430 16724960 PMC1559456
  42. [49]Vassileva G Hu W Hoos L Tetzloff G Yang S Liu L Kang L Davis HR Hedrick JA Lan H Kowalski T Gustafson EL Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice J Endocrinol 2010 205 225 232 20354075
  43. [50]Pathak P Liu H Boehme S Xie C Krausz KW Gonzalez F Chiang JYL Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism J Biol Chem 2017 292 11055 11069 28478385 PMC5491788
  44. [51]Pathak P Li T Chiang JY Retinoic acid-related orphan receptor α regulates diurnal rhythm and fasting induction of sterol 12α-hydroxylase in bile acid synthesis J Biol Chem 2013 288 37154 37165 24226095 PMC3873570
  45. [52]Ferrell JM Chiang JY Circadian rhythms in liver metabolism and disease Acta Pharm Sin B 2015 5 113 122 26579436 PMC4629216
  46. [53]Ferrell JM Chiang JY Short-term circadian disruption impairs bile acid and lipid homeostasis in mice Cell Mol Gastroenterol Hepatol 2015 1 664 677 26645046 PMC4669895
  47. [54]Donepudi AC Ferrell JM Boehme S Choi HS Chiang JYL Deficiency of cholesterol 7α-hydroxylase in bile acid synthesis exacerbates alcohol-induced liver injury in mice Hepatol Commun 2017 2 99 112 29404516 PMC5776875
  48. [55]Seok S Fu T Choi SE Li Y Zhu R Kumar S Sun X Yoon G Kang Y Zhong W Ma J Kemper B Kemper JK Transcriptional regulation of autophagy by an FXR-CREB axis Nature 2014 516 108 111 25383523 PMC4257899
  49. [56]Wang Y Ding Y Li J Chavan H Matye D Ni HM Chiang JY Krishnamurthy P Ding WX Li T Targeting the enterohepatic bile acid signaling induces hepatic autophagy via a CYP7A1-AKT-mTOR axis in mice Cell Mol Gastroenterol Hepatol 2016 3 245 260 28275691 PMC5331786
  50. [57]Owen JL Zhang Y Bae SH Farooqi MS Liang G Hammer RE Goldstein JL Brown MS Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase Proc Natl Acad Sci U S A 2012 109 16184 16189 22927400 PMC3479583
  51. [59]Song KH Li T Owsley E Strom S Chiang JY Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression Hepatology 2009 49 297 305 19085950 PMC2614454
  52. [61]Galman C Lundasen T Kharitonenkov A Bina HA Eriksson M Hafstrom I Dahlin M Amark P Angelin B Rudling M The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man Cell Metab 2008 8 169 174 18680716
  53. [63]Xu J Lloyd DJ Hale C Stanislaus S Chen M Sivits G Vonderfecht S Hecht R Li YS Lindberg RA Chen JL Jung DY Zhang Z Ko HJ Kim JK Veniant MM Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice Diabetes 2009 58 250 259 18840786 PMC2606881
  54. [64]Holland WL Adams AC Brozinick JT Bui HH Miyauchi Y Kusminski CM Bauer SM Wade M Singhal E Cheng CC Volk K Kuo MS Gordillo R Kharitonenkov A Scherer PE An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice Cell Metab 2013 17 790 797 23663742 PMC3667496
  55. [65]Pathak P Chiang JYL Sterol 12α-hydroxylase aggravates dyslipidemia by activating the ceramide/mTORC1/SREBP1C pathway via FGF21 and FGF15 Gene Expr 2019 3 19 10.3727/105221619X15529371970455 [Epub] PMC6827038 30890204 · DOI
  56. [66]Li T Chanda D Zhang Y Choi HS Chiang JY Glucose stimulates cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes J Lipid Res 2010 51 832 842 19965590 PMC2842145
  57. [67]Li T Francl JM Boehme S Ochoa A Zhang Y Klaassen CD Erickson SK Chiang JY Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity J Biol Chem 2012 287 1861 1873 22144677 PMC3265867
  58. [68]Slatis K Gafvels M Kannisto K Ovchinnikova O Paulsson-Berne G Parini P Jiang ZY Eggertsen G Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice J Lipid Res 2010 51 3289 3298 20675645 PMC2952569
  59. [69]Kaur A Patankar JV de Haan W Ruddle P Wijesekara N Groen AK Verchere CB Singaraja RR Hayden MR Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1 Diabetes 2015 64 1168 1179 25338812
  60. [70]Bertaggia E Jensen KK Castro-Perez J Xu Y Di Paolo G Chan RB Wang L Haeusler RA Cyp8b1 ablation prevents Western diet-induced weight gain and hepatic steatosis because of impaired fat absorption Am J Physiol Endocrinol Metab 2017 313 E121 E133 28377401 PMC5582885
  61. [71]Sayin SI Wahlstrom A Felin J Jantti S Marschall HU Bamberg K Angelin B Hyotylainen T Oresic M Backhed F Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist Cell Metab 2013 17 225 235 23395169
  62. [72]Wahlstrom A Sayin SI Marschall HU Backhed F Intestinal Crosstalk between bile acids and microbiota and its impact on host metabolism Cell Metab 2016 24 41 50 27320064
  63. [73]Tripathi A Debelius J Brenner DA Karin M Loomba R Schnabl B Knight R The gut-liver axis and the intersection with the microbiome Nat Rev Gastroenterol Hepatol 2018 15 397 411 29748586 PMC6319369
  64. [74]Ikegami T Honda A Reciprocal interactions between bile acids and gut microbiota in human liver diseases Hepatol Res 2018 48 15 27 29150974
  65. [75]Patterson E Ryan PM Cryan JF Dinan TG Ross RP Fitzgerald GF Stanton C Gut microbiota, obesity and diabetes Postgrad Med J 2016 92 286 300 26912499
  66. [77]Qin J Li Y Cai Z Li S Zhu J Zhang F Liang S Zhang W Guan Y Shen D Peng Y Zhang D Jie Z Wu W Qin Y Xue W Li J Han L Lu D Wu P Dai Y Sun X Li Z Tang A Zhong S Li X Chen W Xu R Wang M Feng Q Gong M Yu J Zhang Y Zhang M Hansen T Sanchez G Raes J Falony G Okuda S Almeida M LeChatelier E Renault P Pons N Batto JM Zhang Z Chen H Yang R Zheng W Li S Yang H Wang J Ehrlich SD Nielsen R Pedersen O Kristiansen K Wang J A metagenome-wide association study of gut microbiota in type 2 diabetes Nature 2012 490 55 60 23023125
  67. [78]David LA Maurice CF Carmody RN Gootenberg DB Button JE Wolfe BE Ling AV Devlin AS Varma Y Fischbach MA Biddinger SB Dutton RJ Turnbaugh PJ Diet rapidly and reproducibly alters the human gut microbiome Nature 2014 505 559 563 24336217 PMC3957428
  68. [80]Patankar JV Wong CK Morampudi V Gibson WT Vallance B Ioannou GN Hayden MR Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition Am J Physiol Endocrinol Metab 2018 314 E418 E432 29066462 PMC6008057
  69. [81]Chevre R Trigueros-Motos L Castano D Chua T Corliano M Patankar JV Sng L Sim L Juin TL Carissimo G Ng LFP Yi CNJ Eliathamby CC Groen AK Hayden MR Singaraja RR Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice FASEB J 2018 32 3792 3802 29481310
  70. [82]Gonzalez FJ Jiang C Patterson AD An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease Gastroenterology 2016 151 845 859 27639801 PMC5159222
  71. [83]Jiang C Xie C Li F Zhang L Nichols RG Krausz KW Cai J Qi Y Fang ZZ Takahashi S Tanaka N Desai D Amin SG Albert I Patterson AD Gonzalez FJ Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease J Clin Invest 2015 125 386 402 25500885 PMC4382255
  72. [85]Xie C Jiang C Shi J Gao X Sun D Sun L Wang T Takahashi S Anitha M Krausz KW Patterson AD Gonzalez FJ An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice Diabetes 2017 66 613 626 28223344 PMC5319721
  73. [86]Parseus A Sommer N Sommer F Caesar R Molinaro A Stahlman M Greiner TU Perkins R Backhed F Microbiota-induced obesity requires farnesoid X receptor Gut 2017 66 429 437 26740296 PMC5534765
  74. [87]Sun L Xie C Wang G Wu Y Wu Q Wang X Liu J Deng Y Xia J Chen B Zhang S Yun C Lian G Zhang X Zhang H Bisson WH Shi J Gao X Ge P Liu C Krausz KW Nichols RG Cai J Rimal B Patterson AD Wang X Gonzalez FJ Jiang C Gut microbiota and intestinal FXR mediate the clinical benefits of metformin Nat Med 2018 24 1919 1929 30397356 PMC6479226
  75. [88]Fang S Suh JM Reilly SM Yu E Osborn O Lackey D Yoshihara E Perino A Jacinto S Lukasheva Y Atkins AR Khvat A Schnabl B Yu RT Brenner DA Coulter S Liddle C Schoonjans K Olefsky JM Saltiel AR Downes M Evans RM Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance Nat Med 2015 21 159 165 25559344 PMC4320010
  76. [89]Pathak P Xie C Nichols RG Ferrell JM Boehme S Krausz KW Patterson AD Gonzalez FJ Chiang JYL Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism Hepatology 2018 68 1574 1588 29486523 PMC6111007
  77. [90]Yang JY Lee YS Kim Y Lee SH Ryu S Fukuda S Hase K Yang CS Lim HS Kim MS Kim HM Ahn SH Kwon BE Ko HJ Kweon MN Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice Mucosal Immunol 2017 10 104 116 27118489
  78. [91]Nauck MA Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am J Med 2011 124 1 Suppl S3 S18 21194578
  79. [92]Ahren B Landin-Olsson M Jansson PA Svensson M Holmes D Schweizer A Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 2004 89 2078 2084 15126524
  80. [93]Trabelsi MS Daoudi M Prawitt J Ducastel S Touche V Sayin SI Perino A Brighton CA Sebti Y Kluza J Briand O Dehondt H Vallez E Dorchies E Baud G Spinelli V Hennuyer N Caron S Bantubungi K Caiazzo R Reimann F Marchetti P Lefebvre P Backhed F Gribble FM Schoonjans K Pattou F Tailleux A Staels B Lestavel S Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells Nat Commun 2015 6 7629 26134028 PMC4579574
  81. [94]Schauer PR Bhatt DL Kirwan JP Wolski K Aminian A Brethauer SA Navaneethan SD Singh RP Pothier CE Nissen SE Kashyap SR STAMPEDE Investigators Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes N Engl J Med 2017 376 641 651 28199805 PMC5451258
  82. [96]Pournaras DJ Glicksman C Vincent RP Kuganolipava S Alaghband-Zadeh J Mahon D Bekker JH Ghatei MA Bloom SR Walters JR Welbourn R le Roux CW The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control Endocrinology 2012 153 3613 3619 22673227 PMC3404349
  83. [97]Risstad H Kristinsson JA Fagerland MW le Roux CW Birkeland KI Gulseth HL Thorsby PM Vincent RP Engstrom M Olbers T Mala T Bile acid profiles over 5 years after gastric bypass and duodenal switch: results from a randomized clinical trial Surg Obes Relat Dis 2017 13 1544 1553 28756050
  84. [99]Nemati R Lu J Dokpuang D Booth M Plank LD Murphy R Increased bile acids and FGF19 after sleeve gastrectomy and Roux-en-Y gastric bypass correlate with improvement in type 2 diabetes in a randomized trial Obes Surg 2018 28 2672 2686 29987678
  85. [100]Bozadjieva N Heppner KM Seeley RJ Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery Diabetes 2018 67 1720 1728 30135133 PMC6463577
  86. [101]Gerhard GS Styer AM Wood GC Roesch SL Petrick AT Gabrielsen J Strodel WE Still CD Argyropoulos G A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass Diabetes Care 2013 36 1859 1864 23801799 PMC3687273
  87. [102]Gomez-Ambrosi J Gallego-Escuredo JM Catalan V Rodriguez A Domingo P Moncada R Valenti V Salvador J Giralt M Villarroya F Fruhbeck G FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss Clin Nutr 2017 36 861 868 27188262
  88. [103]Ryan KK Tremaroli V Clemmensen C Kovatcheva-Datchary P Myronovych A Karns R Wilson-Perez HE Sandoval DA Kohli R Backhed F Seeley RJ FXR is a molecular target for the effects of vertical sleeve gastrectomy Nature 2014 509 183 188 24670636 PMC4016120
  89. [104]McGavigan AK Garibay D Henseler ZM Chen J Bettaieb A Haj FG Ley RE Chouinard ML Cummings BP TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice Gut 2017 66 226 234 26511794 PMC5512436
  90. [105]Albaugh VL Banan B Antoun J Xiong Y Guo Y Ping J Alikhan M Clements BA Abumrad NN Flynn CR Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery Gastroenterology 2019 156 1041 1051 30445014 PMC6409186
  91. [106]Dao MC Everard A Aron-Wisnewsky J Sokolovska N Prifti E Verger EO Kayser BD Levenez F Chilloux J Hoyles L MICRO-Obes Consortium Dumas ME Rizkalla SW Dore J Cani PD Clement K Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology Gut 2016 65 426 436 26100928
  92. [107]Schneeberger M Everard A Gomez-Valades AG Matamoros S Ramirez S Delzenne NM Gomis R Claret M Cani PD Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice Sci Rep 2015 5 16643 26563823 PMC4643218
  93. [108]Adrian TE Gariballa S Parekh KA Thomas SA Saadi H Al Kaabi J Nagelkerke N Gedulin B Young AA Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers Diabetologia 2012 55 2343 2347 22696033
  94. [109]Mueller M Thorell A Claudel T Jha P Koefeler H Lackner C Hoesel B Fauler G Stojakovic T Einarsson C Marschall HU Trauner M Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity J Hepatol 2015 62 1398 1404 25617503 PMC4451470
  95. [110]Hirschfield GM Mason A Luketic V Lindor K Gordon SC Mayo M Kowdley KV Vincent C Bodhenheimer HC Jr Pares A Trauner M Marschall HU Adorini L Sciacca C Beecher-Jones T Castelloe E Bohm O Shapiro D Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid Gastroenterology 2015 148 751 761 25500425
  96. [111]Neuschwander-Tetri BA Loomba R Sanyal AJ Lavine JE Van Natta ML Abdelmalek MF Chalasani N Dasarathy S Diehl AM Hameed B Kowdley KV McCullough A Terrault N Clark JM Tonascia J Brunt EM Kleiner DE Doo E NASH Clinical Research Network Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 2015 385 956 965 25468160 PMC4447192
  97. [114]Pellicciari R Gioiello A Macchiarulo A Thomas C Rosatelli E Natalini B Sardella R Pruzanski M Roda A Pastorini E Schoonjans K Auwerx J Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity J Med Chem 2009 52 7958 7961 20014870
  98. [115]Pols TW Nomura M Harach T Lo Sasso G Oosterveer MH Thomas C Rizzo G Gioiello A Adorini L Pellicciari R Auwerx J Schoonjans K TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading Cell Metab 2011 14 747 757 22152303 PMC3627293
  99. [117]Carino A Cipriani S Marchiano S Biagioli M Santorelli C Donini A Zampella A Monti MC Fiorucci S BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis Sci Rep 2017 7 42801 28202906 PMC5311892
  100. [118]Zambad SP Tuli D Mathur A Ghalsasi SA Chaudhary AR Deshpande S Gupta RC Chauthaiwale V Dutt C TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity Diabetes Metab Syndr Obes 2013 7 1 14 24379686 PMC3873233
  101. [119]Miyazaki-Anzai S Masuda M Kohno S Levi M Shiozaki Y Keenan AL Miyazaki M Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation J Lipid Res 2018 59 1709 1713 29976576 PMC6121929
  102. [120]Ferrell JM Pathak P Boehme S Gilliland T Chiang JYL Deficiency of both farnesoid X receptor and takeda g protein-coupled receptor 5 exacerbated liver fibrosis in mice Hepatology 2019 1 21 10.1002/hep.30513 [Epub] PMC6642864 30664797 · DOI · Paper page
  103. [121]Smushkin G Sathananthan M Piccinini F Dalla Man C Law JH Cobelli C Zinsmeister AR Rizza RA Vella A The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes Diabetes 2013 62 1094 1101 23250357 PMC3609563
  104. [122]Potthoff MJ Potts A He T Duarte JA Taussig R Mangelsdorf DJ Kliewer SA Burgess SC Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice Am J Physiol Gastrointest Liver Physiol 2013 304 G371 G380 23257920 PMC3566618
  105. [123]Herrema H Meissner M van Dijk TH Brufau G Boverhof R Oosterveer MH Reijngoud DJ Muller M Stellaard F Groen AK Kuipers F Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice Hepatology 2010 51 806 816 19998408
  106. [124]Staels B Kuipers F Bile acid sequestrants and the treatment of type 2 diabetes mellitus Drugs 2007 67 1383 1392 17600387
  107. [125]Hansen M Sonne DP Mikkelsen KH Gluud LL Vilsboll T Knop FK Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials J Diabetes Complications 2017 31 918 927 28238556
  108. [126]Fu L John LM Adams SH Yu XX Tomlinson E Renz M Williams PM Soriano R Corpuz R Moffat B Vandlen R Simmons L Foster J Stephan JP Tsai SP Stewart TA Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes Endocrinology 2004 145 2594 2603 14976145
  109. [127]Perry RJ Lee S Ma L Zhang D Schlessinger J Shulman GI FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis Nat Commun 2015 6 6980 25916467 PMC4413509
  110. [129]Zhou M Learned RM Rossi SJ DePaoli AM Tian H Ling L Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice Hepatol Commun 2017 1 1024 1042 29404440 PMC5721409
  111. [131]Yilmaz Y Eren F Yonal O Kurt R Aktas B Celikel CA Ozdogan O Imeryuz N Kalayci C Avsar E Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease Eur J Clin Invest 2010 40 887 892 20624171
  112. [132]Kharitonenkov A Shanafelt AB FGF21: a novel prospect for the treatment of metabolic diseases Curr Opin Investig Drugs 2009 10 359 364 19337957
  113. [133]Talukdar S Zhou Y Li D Rossulek M Dong J Somayaji V Weng Y Clark R Lanba A Owen BM Brenner MB Trimmer JK Gropp KE Chabot JR Erion DM Rolph TP Goodwin B Calle RA A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects Cell Metab 2016 23 427 440 26959184
  114. [135]Widlansky ME Puppala VK Suboc TM Malik M Branum A Signorelli K Wang J Ying R Tanner MJ Tyagi S Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy Vasc Med 2017 22 189 196 28145158 PMC5609820
  115. [136]Smits MM van Raalte DH Tonneijck L Muskiet MH Kramer MH Cahen DL GLP-1 based therapies: clinical implications for gastroenterologists Gut 2016 65 702 711 26786687

Cited by

Sorted by citations

Authors
Ferrell, J. M., & Chiang, J. Y. L.
Affiliations
Northeast Ohio Medical University (US)
Corresponding author
Chiang, John Y. L.
ORCID
Venue
Diabetes & Metabolism Journal
Publisher
Korean Diabetes Association
Published
2019
Volume
43
Issue
3
Pages
257
ISSN
  • 2233-6079 (ISSN-L)
  • 2233-6087
DOI
10.4093/dmj.2019.0043
PMC
PMC6581552
OpenAlex
W2953324747
Cited by
139
References
21
Citations by year
2026: 13 · 2025: 24 · 2024: 20 · 2023: 17 · 2022: 23 · 2021: 16 · 2020: 23 · 2019: 1 · 2018: 1
FWCI
1.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes & Metabolism Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (DK44442, DK58379)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
bile acid signaling, diabetes mellitus, obesity, non-alcoholic fatty liver disease, gut microbiota, dysbiosis, farnesoid X receptor, TGR5, bile acid homeostasis, intestinal barrier, nutrient sensing, energy homeostasis, glucose homeostasis, lipid homeostasis, therapeutic target
MeSH terms
Gastrointestinal Microbiome, Animals, Bile Acids and Salts, Diabetes Mellitus, Type 2, Humans, Liver, Obesity, Signal Transduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review